Gennova Biopharmaceuticals Ltd., a pioneering company in mRNA technology and vaccine development, is proud to announce a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). This collaboration will support the development of AI-enhanced self-amplifying mRNA (sa-mRNA) vaccines to combat some of the world’s deadliest infectious diseases.

The funding and technical support from CEPI will accelerate Gennova’s ongoing efforts to harness artificial intelligence in designing next-generation sa-mRNA vaccine candidates that are rapid to develop, scalable in production, and effective in response to emerging infectious threats.

“This partnership marks a pivotal moment for us,” said Dr. Sanjay Singh, Chief Executive Officer of Gennova Biopharmaceuticals in their post on Linkedin “With CEPI’s support, we are reinforcing our commitment to cutting-edge mRNA innovation that can revolutionize the way the world responds to pandemics and deadly viral outbreaks. Together, we aim to strengthen global health security and safeguard vulnerable populations.”

CEPI’s investment is part of its broader goal to accelerate the development of vaccines that could be deployed rapidly in response to new epidemic and pandemic threats, including the “Disease X” category.

Gennova’s proprietary sa-mRNA platform, now integrated with AI-powered design and optimization, offers the potential for lower doses, faster immune response, and streamlined manufacturing — making it a vital tool in the global arsenal against infectious diseases.